Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Nimesulide (formerly R-805; R 805; R805), a non-steroidal anti-inflammatory drug (NSAID), is a potent and selective COX-2 inhibitor with analgesic and antipyretic properties. It inhibits COX-2 with an IC50 of 26 μM. Nimesulide has been approved for the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. It works by blocking the production of prostaglandins (a chemical associated with pain) thereby relieving pain and inflammation.
ln Vitro |
Nimesulide exhibits a limited effect on COX-1 (IC50 >100 μM), but it is a selective inhibitor of COX-2 with IC50s ranging from 70 nM to 70 μM in a time-dependent manner[1]. In endometrial cancer cells, imimezolide (10 μM) significantly reduces VEGF, while having no effect on normal cells. Nimesulide (10 and 50 µM) significantly lowers MCP-1 levels in normal cells; 10 µM has the same effect on cancer cells. Moreover, mesulide (50 µM) has little effect on cancer cells but has a strong effect on the amount of IL-8 in normal cells[3].
|
||
---|---|---|---|
ln Vivo |
In rats, imesulide (3 and 10 mg/kg, ip) significantly prevents fever brought on by an intraperitoneal injection of LPS. Nimesulide (3 mg/kg, ip) potently suppresses the fever response brought on by TNF-α, IL-1β, or IL-6, but it has no effect on the arachidonic acid-induced initial spike in the fever response. Additionally, mesulide dramatically lowers PGE2 and PGF2α levels in the brain fluid of rats treated with lipopolysaccharide (LPS) and 97% suppresses the rise in plasma TNF-α[2].
|
||
Animal Protocol |
|
||
ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Rapidly absorbed following oral administration. Renal (50%), fecal (29%) Metabolism / Metabolites Hepatic. Extensive biotransformation, mainly to 4-hydroxynimesulide (which also appears to be biologically active). Biological Half-Life 1.8–4.7 hours |
||
Toxicity/Toxicokinetics |
Hepatotoxicity
Prospective studies show that up to 15% of patients taking NSAIDs experience at least transient serum aminotransferase elevations. A lower rate has been reported with nimesulide. These elevations are generally transient, mild and asymptomatic, and may resolve even with drug continuation. Marked aminotransferase elevations (>3 fold elevated) occur in Likelihood score: A (well established cause of clinically apparent liver injury). Protein Binding >97.5% |
||
References |
|
||
Additional Infomation |
Nimesulide is an aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups. It has a role as a cyclooxygenase 2 inhibitor and a non-steroidal anti-inflammatory drug. It is a C-nitro compound, a sulfonamide and an aromatic ether. It is functionally related to a nitrobenzene.
Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries. Nimesulide is a nonsteroidal antiinflammatory drug (NSAID) with relative specificity for COX-2 that is not available in the United States, but is used widely in other countries in the treatment of acute pain. Nimesulide has been linked to a low rate of transient serum enzyme elevations during therapy, but also to many instances of clinically apparent acute liver injury that can be severe and can result in acute liver failure, need for emergency liver transplantation and death. Nimesulide is a nonsteroidal arylsulfonamide with anti-inflammatory properties. Nimesulide inhibits the cyclooxygenase-mediated conversion of arachidonic acid to pro-inflammatory prostaglandins. Modestly selective for COX-2, this agent binds to the enzyme, thereby inactivating it. Nimesulide may inhibit some carcinogenic COX-2-related carcinogenic effects on xenobiotic metabolism, apoptosis, immune surveillance and angiogenesis (overexpressed COX-2 in tumor epithelial cells enhances production of vascular growth factors and the formation of capillary-like networks). (NCI04) Drug Indication For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Mechanism of Action The therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine. Pharmacodynamics Food, gender and advanced age have negligible effects on nimesulide pharmacokinetics. |
Molecular Formula |
C13H12N2O5S
|
|
---|---|---|
Molecular Weight |
308.31
|
|
Exact Mass |
308.046
|
|
CAS # |
51803-78-2
|
|
Related CAS # |
Nimesulide-d5;1330180-22-7
|
|
PubChem CID |
4495
|
|
Appearance |
Light yellow to yellow solid powder
|
|
Density |
1.5±0.1 g/cm3
|
|
Boiling Point |
442.0±55.0 °C at 760 mmHg
|
|
Melting Point |
140-146°C
|
|
Flash Point |
221.1±31.5 °C
|
|
Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
|
Index of Refraction |
1.638
|
|
LogP |
3.79
|
|
Hydrogen Bond Donor Count |
1
|
|
Hydrogen Bond Acceptor Count |
6
|
|
Rotatable Bond Count |
4
|
|
Heavy Atom Count |
21
|
|
Complexity |
450
|
|
Defined Atom Stereocenter Count |
0
|
|
InChi Key |
HYWYRSMBCFDLJT-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3
|
|
Chemical Name |
N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2435 mL | 16.2174 mL | 32.4349 mL | |
5 mM | 0.6487 mL | 3.2435 mL | 6.4870 mL | |
10 mM | 0.3243 mL | 1.6217 mL | 3.2435 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01745614 | Completed | Drug: Nimesulide 100 mg tablets | Pain | GlaxoSmithKline | July 18, 2010 | Phase 1 |
NCT01257126 | Withdrawn | Drug: diclofenac potassium Drug: nimesulide |
Upper Respiratory Tract Infections | Novartis Pharmaceuticals | April 2011 | Phase 4 |
NCT04609748 | Unknown † | Drug: Cannabidiol Oil Drug: Nimesulide |
emporomandibular Joint Disorders Temporomandibular Joint Dysfunction Syndrome Temporomandibular Joint Pain |
Pomeranian Medical University Szczecin | January 27, 2021 | Phase 2 |
NCT02229747 | Completed | Drug: Meloxicam Drug: Diclofenac Drug: Nimesulide |
Pharyngitis | Boehringer Ingelheim | August 2001 | Phase 4 |
NCT01306708 | Completed | Drug: amitriptyline | Adhesive Capsulitis | Universidade do Sul de Santa Catarina | February 2011 | Phase 2 |